Hypertension Unit, Hospital 12 de Octubre, Av. Córdoba s/n, Madrid, Spain.
Curr Hypertens Rep. 2011 Feb;13(1):74-8. doi: 10.1007/s11906-010-0166-7.
Lowering blood pressure by pharmacologic intervention reduces the incidence of cardiovascular events. Nevertheless, despite the widespread availability of effective antihypertensive medications, the vast majority of hypertensive patients worldwide continue to have inadequate blood pressure control. The development of new antihypertensive drugs could contribute to improving the hypertension control rate, and the blockade of new pathophysiologic pathways involved in blood pressure regulation would offer additional benefits. The dual inhibition of the angiotensin II receptor and neprilysin could provide clinical benefits in a range of cardiovascular diseases, including hypertension and heart failure.
通过药物干预降低血压可减少心血管事件的发生。然而，尽管有广泛可用的有效降压药物，全世界绝大多数高血压患者的血压控制仍不理想。开发新的降压药物可能有助于提高高血压控制率，而阻断新的参与血压调节的病理生理途径将带来额外的益处。血管紧张素 II 受体和 Neprilysin 的双重抑制可能为包括高血压和心力衰竭在内的一系列心血管疾病提供临床获益。
